Valentine’s Day has come and gone, but it’s never too late to focus on your heart health. A groundbreaking new study suggests that sotagliflozin, a drug recently approved to treat type 2 diabetes and ...

The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...

The deaths are also partly the result of medical successes: People are living longer, and more people are surviving heart ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

The prevalence of diabetes is increasing faster in some low-income countries than elsewhere in the world, generating concerns ...

Not only does it increase the time it takes ... Viagra is a PDE-5 inhibitor that can help you get an erection if you have erectile dysfunction. It tends to work within one hour and lasts for up to ...

Bayer's position is that Kerendia is not so much in direct competition with the SGLT2 drugs ... In it favour also is that it does not work as a diabetes medicine like the SGLT2s, so patiens ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...